Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia

Diabetes

Volumn 51, Issue 8, 2002, Pages 2377-2386

  Chan, Dick C ^a   Watts, Gerald F ^a,b   Barrett, P Hugh R ^a   Beilin, Lawrence J ^a   Redgrave, Trevor G ^b   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; DIET RESTRICTION; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; INFECTION RISK; INSULIN RESISTANCE; LIPOGENESIS; LIPOPROTEIN METABOLISM; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 0036325388     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.8.2377     Document Type: Article

References (49)

1. Obesity and insulin resistance
2. Insulin resistance and cardiovascular disease
3. Role of insulin resistance in human disease
4. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
5. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
6. Recent advances in our understanding of insulin action and insulin resistance
7. Fatty acid regulation of very low density lipoprotein production
8. Substrate delivery as a determinant of hepatic apoB secretion
9. Role of cholesterol in regulating apolipoprotein B secretion by the liver
10. Insulin sensitivity and atherosclerosis
11. Statin trials and goals of cholesterol-lowering therapy
12. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
13. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolenua heterozygotes
14. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects
15. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: Pathophysiological and therapeutic implications
16. n-3 fatty acids and serum lipoproteins: Human studies
17. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
18. Suppression by diets rich in fish oil of very low density lipoprotein production in man
19. Omega-3 polyunsaturated fatty acid regulation of gene expression
20. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males
21. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
22. Blood volume
23. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity
24. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men
25. Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma
26. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
27. Analysis of native and oxidized low-density lipoprotein oxysterols using gas chromatography-mass spectrometry with selective ion monitoring
28. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men
29. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
30. Preliminary model for human lipoprotein metabolism in hyperlipoproteinemia
31. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: A stable isotope study
32. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
33. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals
34. Metabolic modes of action of the statins in the hyperlipoproteinemias
35. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion
36. Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein
37. Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched diet
38. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases
39. Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitro conversion of very low density lipoproteins to low density lipoproteins
40. The effects of dietary fish oil on hepatic high density and low density lipoprotein receptor activities in the rat
41. Heterogeneity of apolipoprotein B-100-containing lipoproteins: What we have learnt from kinetic studies
42. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase
43. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
44. Statin-induced inhibition of the Rho-signaling pathway activates PPARá and induces HDL apoA-I
45. Dietary fish oils inhibit early events in the assembly of very low density lipoproteins and target apoB for degradation within the rough endoplasmic reticulum of hamster hepatocytes
46. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
47. Do n-3 fatty acids improve glucose tolerance and lipemia in diabetics?
48. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity
49. The biological actions and potential clinical significance of dietary omega-3 fatty acids